Tiziana CEO to present MS trial results November 18

Available on EDGAR 11/12/2026 - 08:08 AM EST Accepted by SEC EDGAR 11/12/2026 - 08:08 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd (TLSA) announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London, taking place November 16–19, 2026. CEO Ivor Elrifi is listed as presenter on November 18 at 14:30 GMT. The presentation will include a company overview and discussion of Phase 2a INFORM-MS results for intranasal foralumab in non-active secondary progressive multiple sclerosis.

Tiziana reported that the trial met its dual primary endpoints, including a statistically significant reduction in microglial activation measured by TSPO PET imaging with the 50 μg dose versus placebo (p=0.0168), alongside a favorable safety and tolerability profile. The company also reported clinically meaningful and statistically significant fatigue improvements on a secondary endpoint. It said 14 patients in an open-label Expanded Access program had been dosed, with improvement or stability of disease seen in all patients within six months.

1 point · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Major pointPhase 2a met dual primary endpoints; TSPO PET result p=0.0168.

Negative

• None.

Key Figures

Conference presentation date: November 18, 2026 Presentation time: 14:30 GMT TSPO PET p-value: p=0.0168 +3 more

6 metrics

Conference presentation date November 18, 2026 Ivor Elrifi's presentation at the Jefferies Healthcare Conference

Presentation time 14:30 GMT Ivor Elrifi's conference presentation

TSPO PET p-value p=0.0168 Reduction in microglial activation with the 50 μg dose versus placebo

Intranasal foralumab dose 50 μg Phase 2a INFORM-MS trial comparison with placebo

Expanded Access patients dosed 14 patients Patients with non-active secondary progressive multiple sclerosis

Reported disease outcome period 6 months Improvement or stability reported for all patients in the Expanded Access program

Key Terms

dual primary endpoints, TSPO PET imaging, microglial activation, Expanded Access program, +1 more

5 terms

dual primary endpoints medical

"the trial met its dual primary endpoints"

TSPO PET imaging medical

"measured by TSPO PET imaging with the 50 μg dose"

TSPO PET imaging is a type of positron emission tomography scan that uses a radiolabeled ligand which binds the 18‑kDa translocator protein (TSPO) to map and quantify TSPO expression in tissues, most commonly the brain; TSPO levels rise in certain activated glial cells, so the PET signal is used as a biomarker of neuroinflammation or glial activation. The scan works by injecting a radioactive tracer that selectively binds TSPO, detecting emitted positrons to create images reflecting where and how much tracer is bound, and then quantifying uptake using measures such as standardized uptake values or kinetic modeling. Limitations include that TSPO expression is not uniquely specific to one cell type or to harmful inflammation, common genetic polymorphisms alter tracer binding affinity and must be accounted for, and accurate quantification often requires careful choice of tracer and modeling (sometimes arterial input), so signals need cautious interpretation.

microglial activation medical

"reduction in microglial activation measured by TSPO PET imaging"

Microglial activation is when the brain’s resident immune cells — microglia — switch from a resting, maintenance role into an alert, defensive state, similar to a neighborhood cleanup crew suddenly racing to douse a small fire. For investors, this matters because persistent or excessive activation is a hallmark of many neurological diseases, affects how drugs perform in trials, and can drive regulatory and market reactions to therapies aimed at calming or harnessing this response.

Expanded Access program medical

"14 patients in an open-label Expanded Access program"

A program that allows patients with serious or life‑threatening conditions to receive an experimental drug or therapy before it is fully approved by regulators, when they cannot join clinical trials. Investors care because expanded access can change a treatment’s market perception, create early real‑world safety or demand signals, and affect regulatory timelines and potential revenue — like a pre‑order system that also reveals how the product performs outside controlled testing.

T regulatory cells medical

"shown to stimulate T regulatory cells when dosed intranasally"

T regulatory cells are a specialized type of immune cell that act like the body’s brake or thermostat, keeping immune responses from becoming too aggressive and preventing damage to healthy tissues. Investors watch them because therapies that boost, suppress, or mimic these cells can treat autoimmune disease, control inflammation, or affect cancer immunotherapy outcomes, so changes in Treg-related science, trial results, or regulation can strongly influence a drug’s safety, effectiveness and market potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TLSA report from the Phase 2a INFORM-MS trial?

Tiziana reported that the trial met its dual primary endpoints, including a statistically significant reduction in microglial activation on TSPO PET imaging with 50 μg intranasal foralumab versus placebo (p=0.0168). It also reported a favorable safety and tolerability profile and clinically meaningful, statistically significant fatigue improvements on a secondary endpoint.

When is TLSA presenting at the Jefferies Healthcare Conference?

Tiziana CEO Ivor Elrifi is listed as presenter on November 18, 2026, at 14:30 GMT, during the Jefferies Healthcare Conference in London, taking place November 16–19, 2026.

How many na-SPMS patients have been dosed in Tiziana's Expanded Access program?

Tiziana said 14 patients with non-active secondary progressive multiple sclerosis had been dosed in its open-label Expanded Access program, with either improvement or stability of disease seen in all patients within six months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2026

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 12, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that members of its senior leadership team will present at the Jefferies Healthcare Conference in London taking place from November 16-19, 2026. The presentation will feature a corporate overview and discussion of the Company’s recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), following the Key Opinion Leader (KOL) call held on November 9, 2026.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: November 12, 2026	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated November 12, 2026

3

Exhibit 99.1

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

BOSTON, MA, November 12, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London taking place from November 16-19, 2026.

The presentation will feature a corporate overview and discussion of the Company’s recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), following the Key Opinion Leader (KOL) call held on November 9, 2026.

Presentation Details

Event: Jefferies Healthcare Conference London

Date: Wednesday, November 18, 2026

Time: 14:30 GMT

Presenter: Ivor Elrifi, Chief Executive Officer

Management will also be available for one-on-one meetings throughout the conference. Interested parties may request meetings through the Jefferies conference portal or by contacting their Jefferies representative.

The recent Phase 2a INFORM-MS trial met its dual primary endpoints, including a statistically significant reduction in microglial activation as measured by TSPO PET imaging with the 50 μg dose of intranasal foralumab versus placebo (p=0.0168), along with a favorable safety and tolerability profile. Clinically meaningful and statistically significant improvements in fatigue were also observed in a secondary endpoint. These results were reviewed in detail during the Company’s KOL call with Tanuja Chitnis, M.D., principal investigator of the INFORM-MS trial, Tarun Singhal M.B.B.S, M.D., M.B.A., the Founding Director, NeuroPET Program Ann Romney Center for Neurologic Diseases, and Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board, Robert L. Kroc Professor of Neurology, Harvard Medical School and Co-Director, Ann Romney Center for Neurologic Diseases, BWH.

A replay of the KOL call is available at: https://edge.media-server.com/mmc/p/7ox8odig

Additional materials and information are available in the Investors section of the Company’s website: https://ir.tizianalifesciences.com/investors

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. Intranasal foralumab is also currently being studied in additional Phase 2 trials in AD, ALS, and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^1,2

¹ https://www.pnas.org/doi/10.1073/pnas.2220272120

² https://www.pnas.org/doi/10.1073/pnas.2309221120

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and statements regarding completion of the INFORM-MS data analysis, presentation of detailed results, engagement with the FDA and potential further clinical development of intranasal foralumab. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd

Paul Spencer, Business Development, and Investor Relations

+44 (0) 207 495 2379

email: info@tizianalifesciences.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 12, 2026 12.9 KB